Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade

This publication has 18 references indexed in Scilit:

• 70 Predictors of antiretroviral-related hepatotoxicity in the adult AIDS clinical trials group (AACTG)
  Hepatology, 2003
• Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001
  AIDS, 2003
• Toxicity of Non-Nucleoside Analogue Reverse Transcriptase Inhibitors
  Seminars in Liver Disease, 2003
• Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine
  HIV Research & Clinical Practice, 2003
• Incidence of and Risk Factors for Severe Hepatotoxicity Associated with Antiretroviral Combination Therapy
  The Journal of Infectious Diseases, 2002
• Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral Suppression
  Clinical Infectious Diseases, 2002
• Rapidly progressive fibrosing cholestatic hepatitis-hepatitis C virus in HIV coinfection
  American Journal of Gastroenterology, 2002
• Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections
  Hepatology, 2002
• Elevated Liver Enzymes Following Initiation of Antiretroviral Therapy
  JAMA, 2000
• Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998
  AIDS, 1999